336 related articles for article (PubMed ID: 15940035)
21. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH
J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164
[TBL] [Abstract][Full Text] [Related]
22. Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Caldés A; Gil-Vernet S; Armendariz Y; Colom H; Pou L; Niubó J; Lladó L; Torras J; Manito N; Rufí G; Grinyó JM
Transpl Infect Dis; 2010 Jun; 12(3):204-12. PubMed ID: 20002612
[TBL] [Abstract][Full Text] [Related]
23. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study.
Manuel O; Pascual M; Perrottet N; Lamoth F; Venetz JP; Decosterd LA; Buclin T; Meylan PR
Clin Transplant; 2010; 24(6):794-800. PubMed ID: 20105200
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
[TBL] [Abstract][Full Text] [Related]
25. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
Oppenheimer F; Gonzalez-Molina M; Rubio M
Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
[TBL] [Abstract][Full Text] [Related]
26. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
Bedel AN; Hemmelgarn TS; Kohli R
Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888
[TBL] [Abstract][Full Text] [Related]
27. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
29. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
30. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
31. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
Luan FL; Chopra P; Park J; Norman S; Cibrik D; Ojo A
Transplant Proc; 2006 Dec; 38(10):3673-5. PubMed ID: 17175363
[TBL] [Abstract][Full Text] [Related]
33. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
[TBL] [Abstract][Full Text] [Related]
34. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.
Doesch AO; Repp J; Hofmann N; Erbel C; Frankenstein L; Gleissner CA; Schmidt C; Ruhparwar A; Zugck C; Schnitzler P; Ehlermann P; Dengler TJ; Katus HA
Drug Des Devel Ther; 2012; 6():289-95. PubMed ID: 23091373
[TBL] [Abstract][Full Text] [Related]
35. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
Pescovitz MD
Transpl Infect Dis; 1999; 1 Suppl 1():31-4. PubMed ID: 11565585
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
[TBL] [Abstract][Full Text] [Related]
37. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
[TBL] [Abstract][Full Text] [Related]
38. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
Kalil AC; Freifeld AG; Lyden ER; Stoner JA
PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
[TBL] [Abstract][Full Text] [Related]
40. Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients.
Villeneuve D; Brothers A; Harvey E; Kemna M; Law Y; Nemeth T; Gantt S
Pediatr Transplant; 2013 Feb; 17(1):80-5. PubMed ID: 23240598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
